• Corpus ID: 6088214

Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.

  title={Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.},
  author={Thorir D. Bjornsson and D. E. Schneider and Ann Hecht},
  journal={The Journal of pharmacology and experimental therapeutics},
  volume={245 3},
This investigation compares the anticoagulant activities and in vivo disposition characteristics of N-deacetylated heparin and N-desulfated heparin with those of standard heparin in an animal model. The N-deacetylated heparin retained 23% of the anticoagulant activity, 34% of the anti-Xa activity and 23% of the anti-IIa activity of standard heparin, whereas the N-desulfated heparin retained only 1.5% of the anticoagulant activity, 0.095% of the anti-Xa activity and 0.92% of the anti-IIa… 
N-desulfated heparin improves concanavalin A-induced liver injury partly through inhibiting T lymphocyte adhesion
N-desulfated heparin may improve immunological liver injury partly via reducing the functions, such as the adhesion to ECM, of T lymphocytes.
N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo
The N-desulfated heparin has the lowest anticoagulant activity among LMWH and chemically modifiedHeparin derivatives, while preserving a potent anti-inflammatory activity, and these combined properties appear to suggest it as a safer medicine for treatment of inflammation.
The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.
Pharmacologic Studies on Synthetic Analogues of Heparin with Selective Affinity to Endogenous Serine Protease Inhibitors
The pentasaccharide representing the minimal ATill binding sequence of heparin was observed to inhibit factor Xa but not thrombin via activation of A TIIl, and GL-522-Y-l also promoted the inhibition of throm bin via HCII but did not interact with A Tiii.
Heparin Pharmacokinetics and Pharmacodynamics
Both forms of heparin are useful antithrombotic agents; however, the correlation between the antithROMbotic effect and an in vitro laboratory test for either type still needs further clarification.
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Three addi- tional parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to hep- arin in patients with HIT and fonda- parinux-associated HIT or osteoporosis is unlikely to occur.
Heparin Binds to Lipopolysaccharide (LPS)-Binding Protein, Facilitates the Transfer of LPS to CD14, and Enhances LPS-Induced Activation of Peripheral Blood Monocytes1
It is shown that clinically used heparin preparations significantly enhance the ability of LBP to catalytically disaggregate and transfer LPS to CD14, the LPS receptor, and this novel anticoagulant drug is a potential candidate for safe administration to patients who have endotoxemia and require antICOagulation.
Heparin-stimulated expression of extracellular-superoxide dismutase in human fibroblasts.
Heparin and Other Indirect Antithrombin Agents
Heparin has the distinction of being the oldest antithrombotic and, along with a number of the agents, it is identified as an indirect antithROMbotic agent because it inhibits thrombin via the potentiation of an endogenously occurring natural inhibitor.